SCHEMBL2193522

SCHEMBL2193522

Cc1c(F)cccc1Nc1nc(O)ccc1N

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.39
PIK3C2B O00750 1/20 0.39
MTOR P42345 1/20 0.39
PIK3CG P48736 1/20 0.39
OPRM1 P35372 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CXCR2 P25025 2/20 0.34
MAPT P10636 3/20 0.34
AURKA O14965 1/20 0.34
P2RX7 Q99572 1/20 0.34
NUDT1 P36639 1/20 0.33
CFTR P13569 1/20 0.33
RECQL P46063 1/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33
LYN P07948 1/20 0.32
BTK Q06187 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192677 0.85 EGFR (0.38) GAAMAPTHTT
SCHEMBL2191767 0.85 NUDT1 (0.47) ALDH1A1GAASMN1; SMN2MAPTNUDT1
SCHEMBL2192476 0.85 MAPT (0.44) ALDH1A1SMN1; SMN2MAPTAURKARECQL
SCHEMBL2192571 0.83 MAPT (0.50) ALDH1A1GAAMAPTP2RX7
SCHEMBL2194873 0.83 CXCR2 (0.40) PIK3CDPIK3CGALDH1A1GAASMN1; SMN2
SCHEMBL2193095 0.78 MEN1 (0.44) ALDH1A1GAASMN1; SMN2MAPTHTT
SCHEMBL2194676 0.77 NUDT1 (0.33) ALDH1A1GAAMAPTAURKANUDT1
SCHEMBL2196525 0.75 EPHX2 (0.48) ALDH1A1GAASMN1; SMN2MAPTTP53
SCHEMBL2193574 0.74 KHK (0.39) ALDH1A1SMN1; SMN2MAPTTP53HTT
SCHEMBL2193744 0.73 PDE5A (0.46) ALDH1A1SMN1; SMN2MAPTAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507473-B2 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders ARENA PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2011-07-14 US disclosed
WO-2010030360-A1 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS ARENA PHARMACEUTICALS, INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172209-A1 3H-IMIDAZO[4,5-B]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS GPR84, GPR119, GPR65 PIK3CD 1678/4885PIK3C2B 1853/4885MTOR 2619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.